RxDoctor Payments Data

Gisela Trigo, MD

Cardiovascular Disease · Inverness, FLNPI 1366426561

Payments from drug & device makers

$2,925in general payments, 2019–2025

Across 101 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$887
  • Abbott$708
  • Boston Scientific$549
  • Pfizer$117
  • Amarin Pharma, Inc.$113
  • Impulse Dynamics (USA) Inc.$87
  • plus $463 from 13 others

What the payments were for

  • Food & beverage$2,88699%
  • Other$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,925 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$205,996
Medicare patients
505
Services billed
2,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$275,840
XareltoRivaroxaban111$140,546
EntrestoSacubitril/Valsartan53$61,660
MultaqDronedarone Hcl16$23,101
Repatha SureclickEvolocumab18$13,410
Metoprolol Succinate196$3,897
Propafenone Hcl21$2,800
Ranolazine ErRanolazine20$2,476
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$1,826
Dabigatran EtexilateDabigatran Etexilate Mesylate12$1,741
Metoprolol Tartrate209$1,691
Flecainide Acetate35$1,624
Atorvastatin Calcium127$1,616
Amiodarone Hcl54$1,517
Diltiazem 12hr ErDiltiazem Hcl14$1,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$275,840232 claims
Johnson & JohnsonXarelto$68$140,546111 claims
NovartisEntresto$35$61,66053 claims
Sanofi-aventis U.S. LLCMultaq$14$23,10116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Inverness

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →